PMID- 24527947
OWN - NLM
STAT- MEDLINE
DCOM- 20141010
LR  - 20191210
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 10
IP  - 3
DP  - 2014 Mar
TI  - A new intravenous immunoglobulin (BIVIGAM(R)) for primary humoral immunodeficiency.
PG  - 325-37
LID - 10.1586/1744666X.2014.891438 [doi]
AB  - Human immunoglobulin G administered intravenously or subcutaneously is used to 
      prevent infections in patients with primary antibody deficiencies. Intravenous 
      immunoglobulin (IVIG) preparations have improved over the years and have evolved 
      from immune serum globulin that is injected intramuscularly or subcutaneously at 
      relatively low doses (100-150 mg/kg per month). IVIG products are currently 
      available in different concentrations and compositions and can deliver up to 2 
      g/kg or more per infusion with few side effects. This report describes the 
      properties and clinical trial results of BIVIGAM((R)), a new IVIG product. We also 
      discuss how improvements in intravenous immunoglobulin manufacturing and 
      formulation have improved clinical outcomes in patients with primary 
      immunodeficiencies, also benefiting patients with other immunological disorders.
FAU - Wasserman, Richard L
AU  - Wasserman RL
AD  - Pediatric Allergy/Immunology Associates, 777 Forest Lane, Suite B-332, Dallas, 
      75230 TX, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Immunoglobulins)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *Immunity, Humoral/drug effects/genetics
MH  - Immunoglobulins/*deficiency
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Deficiency Syndromes/complications/immunology/*therapy
MH  - Infection Control/*methods
MH  - Infections/etiology
EDAT- 2014/02/18 06:00
MHDA- 2014/10/11 06:00
CRDT- 2014/02/18 06:00
PHST- 2014/02/18 06:00 [entrez]
PHST- 2014/02/18 06:00 [pubmed]
PHST- 2014/10/11 06:00 [medline]
AID - 10.1586/1744666X.2014.891438 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2014 Mar;10(3):325-37. doi: 
      10.1586/1744666X.2014.891438.